Addition of leukotriene antagonists or long-acting β2-agonists to inhaled corticosteroid therapy in asthma treatment increases drug costs without decreasing service-related costs Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001
Concomitant use of long-acting beta-agonists with inhaled corticosteroids among asthma patients in the UK primary care Source: Annual Congress 2007 - Miscellaneous epidemiological aspects of respiratory disease Year: 2007
De-implementing inappropriate inhaled steroids use in Dutch COPD patients in primary care Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019
Prescribing patterns of inhaled corticosteroids in asthma amongst primary care physicians in Singapore Source: Virtual Congress 2021 – Primary care organisation and epidemiology Year: 2021
Regular use of inhaled corticosteroids and the long-term prevention of hospitalisation for asthma Source: Eur Respir J 2002; 20: Suppl. 38, 8s Year: 2002
Long-acting β2 -agonists provide greater benefit compared to leukotriene antagonists when added to inhaled corticosteroids in patients with symptomatic asthma Source: Eur Respir J 2004; 24: Suppl. 48, 310s Year: 2004
SABA and ICS use among mild asthma patients in UK primary care Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies Year: 2019
Inhaled steroids prescribing in patients with COPD in the community Source: Eur Respir J 2001; 18: Suppl. 33, 59s Year: 2001
SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting ß2 -agonist use in asthma Source: Eur Respir J, 55 (2) 1901858; 10.1183/13993003.01858-2019 Year: 2020
Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007
Asthma and once-daily administration of inhaled corticosteroids: potential for improved compliance and reduced health costs Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002
Switching to maintenance and reliever inhaled corticosteroid/long acting beta agonist: a real-world pilot evaluation in a regional paediatric difficult asthma clinic. Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world Year: 2020
Considerations about cost-effectiveness and global satisfaction of asthmatic patients treated with montelukast compared with inhaled corticosteroids Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002
Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use? Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007
Inappropriate overuse of inhaled corticosteroids in patients with moderate COPD in UK primary care Source: Annual Congress 2011 - Disease management in specific primary care populations Year: 2011
The use of electronic alerts in primary care to identify the over-prescription of short-acting beta2-agonists in people with asthma: a systematic review Source: International Congress 2017 – Primary care management of asthma and COPD Year: 2017
Stepping-down inhaled corticosteroid therapy in stable asthma: a secondary care perspective Source: Eur Respir J 2005; 26: Suppl. 49, 277s Year: 2005
COPD guides and inhaled corticosteroids. Is there an adequate use in primary care? Source: International Congress 2016 – Targeting care, pulmonary rehabilitation, management, and self-management of COPD exacerbations in primary care Year: 2016
Predictors of inhaled corticosteroid therapy in COPD alone compared to COPD with concomitant asthma managed in primary care Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019